Jump to content

EF-1502

From Wikipedia, the free encyclopedia
EF-1502
Names
IUPAC name
4-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl-methylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • InChI=1S/C22H26N2O2S2/c1-14-9-12-27-20(14)16(21-15(2)10-13-28-21)6-5-11-24(3)17-7-4-8-18-19(17)22(25)23-26-18/h6,9-10,12-13,17H,4-5,7-8,11H2,1-3H3,(H,23,25)
    Key: CUESOMOCKVRNIW-UHFFFAOYSA-N
  • CC1=C(SC=C1)C(=CCCN(C)C2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
Properties
C22H26N2O2S2
Molar mass 414.58 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

EF-1502 is a GABA reuptake inhibitor. It could potentially be used to treat seizures.

Mechanism of action

[edit]

EF-1502 has been shown to inhibit the type 1 GABA transporter (GAT1)[1] and the Sodium and chloride-dependent betaine transporter (BGT-1).[2]

Potential use

[edit]

Tests in mice have shown that this compound possesses and anticonvulsant effect due to its GABA reuptake inhibiting properties.[3][4]

References

[edit]
  1. ^ Madsen, Karsten K.; White, H. Steve; Schousboe, Arne (March 2010). "Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs". Pharmacology & Therapeutics. 125 (3): 394–401. doi:10.1016/j.pharmthera.2009.11.007. ISSN 1879-016X. PMID 20026354.
  2. ^ Schousboe, Arne; Larsson, Orla M.; Sarup, Alan; White, H. Steve (2004-10-01). "Role of the betaine/GABA transporter (BGT-1/GAT2) for the control of epilepsy". European Journal of Pharmacology. 500 (1–3): 281–287. doi:10.1016/j.ejphar.2004.07.032. ISSN 0014-2999. PMID 15464040.
  3. ^ Madsen, Karsten K.; Hansen, Gert H.; Danielsen, E. Michael; Schousboe, Arne (February 2015). "The subcellular localization of GABA transporters and its implication for seizure management". Neurochemical Research. 40 (2): 410–419. doi:10.1007/s11064-014-1494-9. ISSN 1573-6903. PMID 25519681.
  4. ^ Schousboe, Arne; Sarup, Alan; Larsson, Orla M.; White, H. Steve (2004-10-15). "GABA transporters as drug targets for modulation of GABAergic activity". Biochemical Pharmacology. 68 (8): 1557–1563. doi:10.1016/j.bcp.2004.06.041. ISSN 0006-2952. PMID 15451399.